Thursday 10/July/2025 – 05:24 AM
In a scientific discovery, the rules of the game may change in treatment CancerResearchers from the University of Southern California announced promising results for the use of the genetically modified herpes virus (HSV-1) in the treatment of advanced melanoma, one of the most dangerous types of skin cancer, according to what was published in the New York Post.
From the annoying virus to a tool for fighting tumors
The simple type 1 herpes virus is usually known as the cause of the appearance of painful pimples around the mouth, and it is suffered by about two -thirds of the world’s population. But a medical team led by Dr. Jino Kim was able to adjust the virus to become a fierce fighter of cancer cells, without causing harm to healthy tissues.
The new clinical experiment, which included 140 patients with treatment -resistant skin cancer, showed very encouraging results; The size of the tumors decreased by no less than 30% in a third of the participants, while the tumors completely disappeared in 1 out of every 6 patients.
Double treatment mechanism
Treatment depends on the inclusion of a modified virus known as RP1 with Nivolumab, a well -known drug used in immunotherapy.
RP1 works to attack and multiply cancer cells inside and destroy them, while Nevolomab disrupts the proteins that prevent the immune system from getting to identify cancer, allowing it to effectively attack the tumor.
More importantly, the researchers noted that the effect was not limited to the injected tumors only, but also included other tumors that are treated within the body, indicating the response of the comprehensive immune system and its motivation to fight cancer throughout the body.
New hope for advanced cases
Dr. Kim said, half of advanced melanoma does not respond to traditional immunotherapy, and these patients usually run out of their options. These results offer a real glimmer. “
The treatment was well tolerated by patients, and there were no serious complications, and the results of the study were published in the Journal of Clinical Oncology, and was recently presented at the annual meeting of the American Association of Clinical Oncology.
